Table 1 Patients demographics and clinico-pathological characteristics for phase I and II enrolled pancreatic cancer patients (N = 75)
|  | Enrolled patients (N = 75) (%) |
|---|---|
Age group | |
 Median (range) | 62.8 (44–83) |
 < 60 | 27 (36%) |
 ≥ 60 | 48 (64%) |
Sex | |
 Male to female ratio | 1.7:1 |
 Female | 28 (37.3%) |
 Male | 47 (62.7%) |
Race | |
 White | 61 (81.3%) |
 Black | 4 (5.3%) |
 Hispanic | 4 (5.3%) |
 Asian | 4 (5.3%) |
 Others | 2 (2.7%) |
Tumor differentiation | |
 Moderate | 22 (29.3%) |
 Poor | 23 (30.7%) |
 Unknown | 30 (40%) |
ECOG | |
 0 | 8 (10.7%) |
 1 | 67 (89.3%) |
Tumor location | |
 Head | 22 (29.3%) |
 Body | 32 (42.7%) |
 Tail | 19 (25.3%) |
 Unknown | 2 (2.7%) |
Site of metastasis | |
 Liver | 61 (75.3%) |
 Lung | 10 (12.3%) |
 Peritoneal | 15 (18.5%) |
 Others | 4 (5.3%) |
CA19-9 (U/ml) | |
 Median (range) | 58,159.1 (0.9–58,160) |
 ≤ 35 | 12 (16%) |
 > 35 | 63 (84%) |
Previous treatment | |
 De novo | 69 (92%) |
 Surgery | 4 (4.9%) |
 Chemotherapy | 4 (4.9%) |